Clinical takeawayConsider using the capsule-sponge-TFF3 test as a non-invasive screening tool to rule out esophageal adenocarcinoma in patients at risk for Barrett's esophagus, pending further validation in broader populations.
What it foundThe capsule-sponge-TFF3 test had a high negative predictive value (99.7%) for esophageal adenocarcinoma over long-term follow-up compared to standard endoscopic screening.
ContextThis supports the potential utility of the capsule-sponge-TFF3 test as a reliable screening method for select populations, though it does not replace standard diagnostic procedures.
Clinical takeawayConsider adopting CAQ systems for colonoscopy to improve adenoma detection, particularly in settings where ADR is suboptimal. The trade-off is a modest increase in withdrawal time (0.63 minutes). Interpret AADR and ACDR improvements cautiously due to low event rates.
What it foundComputer-aided quality assurance (CAQ) increased adenoma detection rate by 43% (RR 1.43, 95% CI 1.17-1.73) compared to standard colonoscopy.
ContextConfirms prior evidence that enhanced visualization tools improve ADR, with new data suggesting this extends to advanced adenomas (54% increase in AADR) and adenocarcinomas (30% increase in ACDR), though these findings are limited by low event rates.
Refinesthe standard of careACG 2021 / USMSTF 2022 / USPSTF 2021 / CF Foundation
Clinical takeawayConsider duvakitug 900 mg every 2 weeks for adults aged 18-75 with moderately to severely active ulcerative colitis, including those with inadequate response, loss of response, or intolerance to prior therapies, while monitoring for adverse events.
What it foundDuvakitug 900 mg achieved clinical remission in 48% of patients vs 20% with placebo at week 14, with a 26% higher posterior mean response rate (95% CrI 8 to 44). Adverse event incidence was similar to placebo (43% vs 52%).
ContextThis provides new evidence for duvakitug, an anti-TL1A monoclonal antibody, as a potential treatment option in a population with limited response to conventional or advanced therapies.
Emergingthe standard of careAGA 2020 / ACG 2019 / AGA 2024 CPU on positioning
Reinisch W … Jairath V · The lancet. Gastroenterology & hepatology · IF 30.9 · PubMed ↗
Clinical takeawayConsider measuring serum IgA levels in MASLD patients for additional risk stratification, particularly in those without advanced fibrosis but with unexplained disease progression. No clinical action yet: the therapeutic implications of IgA-targeted interventions remain investigational.
What it foundElevated IgA (≥ 318 mg/dL) independently predicted liver-related events in MASLD patients (HR=3.17, 95% CI 1.27-7.91), with a 5-year cumulative incidence of 24.0% vs lower rates in other subgroups.
ContextChallenges the current fibrosis-centric risk assessment in MASLD by identifying an immune-driven high-risk phenotype independent of fibrosis stage, supported by multi-omics validation across cohorts.
Emergingthe standard of careAASLD 2023 MASLD / NLA 2014 statin liver safety
Kimura T … Tanaka N · Journal of hepatology · IF 26.8 · PubMed ↗
Clinical takeawayNo need to modify contraceptive counseling or screening for colorectal cancer based on hormonal contraceptive use in premenopausal women, as modern formulations show no clear protective or harmful effect.
What it foundCurrent or recent hormonal contraceptive use (all types) showed no significant change in colorectal cancer risk (IRR 0.94, 95% CI 0.83-1.06) vs. never users, with similar null effects for progestogen-only pills (IRR 1.09) and levonorgestrel IUDs (IRR 0.96).
ContextRefutes prior hypotheses that hormonal contraception might influence colorectal cancer risk in young women, aligning with recent null findings for modern formulations.
Lange IH … Mørch LS · BMJ (Clinical research ed.) · IF 42.7 · PubMed ↗
Clinical takeawayConsider using the CIRI model as a non-invasive alternative to HVPG for stratifying decompensation risk in cACLD patients, particularly where HVPG or LSM are unavailable. No clinical action yet: requires further validation before widespread adoption.
What it foundCIRI model predicted hepatic decompensation with 1- and 2-year AUROCs of 0.816 and 0.815 in the development cohort (vs. MELD and FIB-4, both p<0.001) and 0.836 and 0.769 in external validation (vs. HVPG, both p>0.900; vs. LSM, both p<0.05), using a cutoff of ≥-8.25 to identify high-risk patients (equivalent to HVPG ≥10mmHg). The model was trained on 11 demographic and routine laboratory parameters (specifics not provided in abstract).
ContextChallenges current reliance on HVPG (invasive) and LSM (infrastructure-dependent) by offering a scalable, non-invasive tool with comparable performance. Study populations included cACLD patients with steatotic liver disease as the leading etiology (54% in development, 44% in validation), with median follow-up of 18.5 and 27.5 months, respectively.
Clinical takeawayConsider cryptogenic SLD as a distinct high-risk phenotype in lean patients (BMI <25 kg/m²) without CMRFs. Monitor these patients for liver injury using non-invasive fibrosis assessment tools (e.g., FIB-4, VCTE, MRE) and consider closer follow-up despite the absence of traditional metabolic risk factors.
What it foundCryptogenic steatotic liver disease (SLD), defined as lean SLD (BMI <25 kg/m²) without cardiometabolic risk factors (CMRFs), was associated with a 2.5-fold increased risk of liver-related death (HR 2.5, 95% CI 1.4 to 4.3) compared to non-SLD/no CMRF in the KNHIS cohort.
ContextThis challenges the assumption that lean SLD without CMRFs is benign, showing it carries a significant liver-related mortality risk, though direct comparison to metabolic-associated SLD was not performed.
Refinesthe standard of careAASLD 2023 Practice Guidance
Clinical takeawayConsider zalfermin 30 mg co-administered with semaglutide 2.4 mg weekly as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis (F2-F4c), pending phase 3 confirmation of efficacy and safety. Monitor for adverse effects as part of clinical trials or post-marketing surveillance.
What it foundZalfermin 30 mg plus semaglutide 2.4 mg achieved a higher proportion of participants with ≥1-stage liver fibrosis improvement (NASH CRN fibrosis scale) and no worsening of metabolic dysfunction-associated steatohepatitis at week 52 compared to placebo (specific percentage not provided in abstract). Adverse effects included [specific adverse effects if mentioned in abstract].
ContextThis study provides new evidence for a combination therapy in a population with limited treatment options, challenging the current standard of care which lacks approved pharmacotherapies for fibrosis in metabolic dysfunction-associated steatohepatitis.
Reinforcesthe standard of careAASLD 2023 Practice Guidance
Loomba R … Gluud LL · The lancet. Gastroenterology & hepatology · IF 30.9 · PubMed ↗
New evidencerct · n=150 · Jul 15, 2026 · Endoscopy
Rigor86
Shift25
Practice80
Standing40
Signal score, how each part rates
Study rigorStrongrct
Journal standingModerateIF 7.7
ShiftModerateAdds to an open question
Practice relevanceStrongBears on a bedside decision
Clinical takeawayFor difficult biliary cannulation in patients with both malignant and benign biliary obstruction, consider double-guidewire (DGT), trans-pancreatic sphincterotomy (TPS), or precut fistulotomy as equally effective salvage options, but weigh DGT's lower pancreatitis risk (10%) against precut's reduced contrast use and higher pancreatitis risk (24%). Base choice on anatomy, operator skill, and resource availability.
What it foundInitial biliary cannulation success rates were similar across techniques (72% DGT, 68% TPS, 68% precut), with 100% final success in all groups; precut used less contrast dye (p<0.005), while post-ERCP pancreatitis rates were numerically higher with TPS (22%) and precut (24%) vs DGT (10%).
ContextConfirms that advanced techniques for difficult cannulation achieve similar success rates in patients with both malignant and benign biliary obstruction despite prior uncertainty about comparative efficacy, though hints at tradeoffs in contrast use and pancreatitis risk.
Emergingthe standard of careACG 2024
Elhoseeny MM … Othman AAA · Gastrointestinal endoscopy · IF 7.7 · PubMed ↗
Clinical takeawayScreen hEDS/HSD patients for chronic GI symptoms (especially heartburn, dysphagia, GERD) following SOC for GERD (alarm feature assessment first, empiric PPI trial if no alarms). Assess for comorbid DGBIs (functional dysphagia 34.2%) and extraintestinal conditions (chronic fatigue 49%, migraine 38.2%, OI 35.9%, POTS 21.9%).
What it found65.3% of hEDS/HSD patients report at least one chronic GI symptom (OR 4.29 vs controls), with heartburn (34.7%), functional dysphagia (34.2%), and GERD (41.3%) most common. Evidence quality is low due to clinical heterogeneity; associations should not be interpreted as causal.
ContextConfirms high prevalence of GI symptoms and DGBIs in hEDS/HSD, previously reported anecdotally; quantifies associations (OR 4.29) and specific symptom rates. Evidence is limited by clinical heterogeneity.
Refinesthe standard of careACG 2022 / AGA 2022 CPU refractory GERD
Kulin D … Shah A · Alimentary pharmacology & therapeutics · IF 7.6 · PubMed ↗
Clinical takeawayGI clinicians involved in training should ensure trainees meet ESGE's structured competency framework before managing UGIB, including simulator training and supervised procedures. No direct clinical action for non-trainers: this is a guideline for endoscopy education.
What it foundThe ESGE position statement outlines 11 specific training requirements for managing acute upper gastrointestinal bleeding (UGIB), including preadoption technical skills, competency assessment, simulator training, and supervised procedures (minimum 20 with endoscopic stigmata of recent hemorrhage).
ContextRefines current training practices by providing a standardized, competency-based approach to UGIB management education, moving beyond numerical thresholds to skill assessment.
Reinforcesthe standard of careACG 2021 UGIB / ACG 2024 H. pylori / ESGE 2021 NVUGIB
Voiosu AM … Gralnek IM · Endoscopy · IF 9.3 · PubMed ↗
Clinical takeawayFor decompensated MASLD/MetALD cirrhosis, prioritize PEth-confirmed alcohol abstinence (PEth >200 ng/mL indicates heavy chronic use), weight loss ≥10%, glycemic control, and variceal screening. Monitor for recompensation potential, especially in patients without large varices or MetALD etiology, where mortality is higher (22.6% vs. 12.0% in MASLD, p=0.011).
What it found18.6% of decompensated MASLD/MetALD cirrhosis patients achieved recompensation (Baveno VII criteria: absence of ascites, hepatic encephalopathy, variceal bleeding, and jaundice), with weight loss ≥10% (sHR 7.42), alcohol abstinence (sHR 1.87), glycemic control (sHR 1.43), and absence of large varices (sHR 1.97) independently associated with recompensation.
ContextConfirms that recompensation is achievable in a subset of decompensated MASLD/MetALD cirrhosis patients, extending prior evidence on metabolic and alcohol-related interventions beyond traditional decompensation management.
Refinesthe standard of careAASLD 2020 Crabb + AGA 2023/2025 CPU (Mellinger) + Mathurin NEJM 2011 + STOPAH NEJM 2015 + ACCELERATE-AH (Lee Gastroenterology 2018) + SALT score (Lee JAMA IM 2019) + Rinella Hepatology 2023 (MetALD nomenclature) + Nguyen-Khac NEJM 2011 (NAC) + CIWA-Ar (Sullivan 1989) + Hendershot JAMA Psych 2025 (semaglutide AUD)
Premkumar M … Reddy KR · Hepatology (Baltimore, Md.) · IF 13.5 · PubMed ↗
New evidencerct · n=195 · Jul 16, 2026 · Colorectal
Clinical takeawayConsider laparoscopic surgery as an acceptable option for symptomatic, non-curable stage IV colon cancer (cecum to rectosigmoid, with stenosis/bleeding and 1-3 non-curable factors), given non-inferiority to open surgery in progression-free survival. Postoperative chemotherapy options include modified FOLFOX6 plus bevacizumab or capecitabine plus oxaliplatin with bevacizumab.
What it found3-year progression-free survival was 5.3% for open surgery vs 3.0% for laparoscopic surgery (HR 1.028, 95% CI 0.772-1.370; p for non-inferiority = 0.02), with 3-year overall survival 31.5% vs 28.5%. Grade ≥3 late complications occurred in 1.1% of open and 2.0% of laparoscopic surgeries.
ContextConfirms laparoscopic resection is non-inferior to open surgery in this population, aligning with prior evidence favoring minimally invasive approaches where feasible. The study was limited by chemotherapy administration without knowledge of microsatellite instability or RAS/BRAF mutation status.
Shiomi A … Inomata M · Diseases of the colon and rectum · IF 3.5 · PubMed ↗
Clinical takeawayWhen diagnosing IBS or CAPS, use the clarified Rome V definition of 'continuous' pain (intermittent episodes without pain-free intervals) rather than 'constant' pain (unremitting).
What it foundThe letter clarifies the definition of 'continuous' abdominal pain in Rome V criteria for IBS and CAPS, distinguishing it from 'constant' pain.
ContextRefines the Rome V criteria by addressing prior ambiguity in terminology, aiding more precise application.
Refinesthe standard of careACG / Rome IV / clinical consensus + AAFP differential
Lembo A … Fukudo S · Gastroenterology · IF 29.4 · PubMed ↗
New evidencereview · Jul 13, 2026 · Pancreas/Biliary
Clinical takeawayConsider molecular profiling for intrahepatic cholangiocarcinoma patients to identify actionable targets such as fibroblast growth factor receptor 2 fusions and isocitrate dehydrogenase 1 or 2 mutations, which may guide targeted therapy decisions.
What it foundIntrahepatic cholangiocarcinomas include distinct molecular subtypes, with fibroblast growth factor receptor 2 fusions and isocitrate dehydrogenase 1 or 2 mutations present in relatively high percentages.
ContextThis refines current practice by highlighting the molecular heterogeneity of intrahepatic cholangiocarcinomas, which differs from the traditional surgical classification and emphasizes the importance of molecular subtyping for personalized treatment.
Refinesthe standard of careNCCN 2024 / AASLD
Braconi C … Roberts LR · Gastroenterology · IF 29.4 · PubMed ↗
New evidenceretrospective · n=169 · Jul 15, 2026 · Esophagus/Reflux
Clinical takeawayIn the palliative setting for malignant esophageal obstruction, consider liquid nitrogen spray cryotherapy with balloon dilation (LNSC) as an alternative to fully covered self-expanding metal stents (FCSEMS), particularly for patients at higher risk of stent-related complications (migration, intolerance). LNSC showed fewer adverse events and a trend toward better dysphagia improvement, though clinical success did not reach statistical significance.
What it foundIn a retrospective cohort study of palliative therapy for malignant esophageal obstruction, clinical success (improvement/stabilization of dysphagia, defined as ≥1-point change on the Ogilvie scale) was 86.8% with liquid nitrogen spray cryotherapy with balloon dilation (LNSC) vs. 71.0% with fully covered self-expanding metal stents (FCSEMS) (p=0.057; OR 2.70, 95% CI 0.93-7.83). Median Ogilvie dysphagia score improved from 3 to 2 with FCSEMS (change -1, IQR 0 to -2) and from 3 to 1 with LNSC (change -2, IQR -1 to -2). Adverse events were significantly lower with LNSC (7.9% vs. 31.3%, p=0.037; aOR 0.21, 95% CI 0.06-0.76 favoring LNSC), classified by ASGE Lexicon severity. FCSEMS had higher rates of stent migration (19.1%) and intolerance requiring removal (7.6%), while LNSC had delayed stricture in 7.9%.
ContextThis retrospective study compares two palliative modalities for malignant esophageal obstruction, suggesting LNSC may be safer than FCSEMS with comparable efficacy. The findings challenge the assumption that FCSEMS is the default palliative option, but the study is limited by its retrospective design and small LNSC cohort (n=38).
Refinesthe standard of careNCCN / ASGE / ACG
Moond V … Thakkar S · Gastrointestinal endoscopy · IF 7.7 · PubMed ↗
New evidenceretrospective · n=3,438 · Jul 16, 2026 · Pancreas/Biliary
Clinical takeawayConsider adjuvant therapy for PDAC patients over 80 years old after pancreatectomy, as it significantly improves survival, but assess individual tolerance and comorbidities. Do not routinely recommend neoadjuvant treatment in this age group based on current evidence, though interpret cautiously due to limited resectability-adjusted data.
What it foundIn PDAC patients over 80 years old, adjuvant therapy (AT) improved median survival to 30.7 months vs 23.7 months without AT (p < 0.001), while neoadjuvant treatment (NAT) showed no significant survival benefit compared to non-NAT (30.5 vs 29.0 months, p = 0.205) in resectability-adjusted analysis.
ContextChallenges the assumption that elderly PDAC patients uniformly benefit from neoadjuvant therapy, while confirming the value of adjuvant treatment in this population. NAT findings are from a resectability-adjusted subgroup (2017 onward) and require cautious interpretation.
Refinesthe standard of careNCCN 2024 + PRODIGE 24 + POLO + NAPOLI-1 + ASCO 2024
Hashimoto D … Takeyama Y · Journal of gastroenterology · IF 6.9 · PubMed ↗
No papers match these filters.
Try removing a filter to widen the view.
Get GI Signals weekly
One short email a week: what is worth knowing in GI, and why. Pick your areas. Double opt-in; unsubscribe anytime.
Every new paper across 48 vetted GI, hepatology, and general-medicine journals.
02
Screen
Filter noise; classify why each paper matters and how strong it is.
03
Read
Draft a bedside takeaway anchored to the relevant standard of care.
04
Verify
An adversarial second pass checks every claim against its cited source.
05
Vet
A physician editor stands behind each card before it publishes.
The first pass is AI-assisted; the judgment is human. Nothing is surfaced or emailed until
Simon Mathews, MD has reviewed it. We show the funnel, the evidence grade, and a primary-source link on
every paper because a source you can check is the only kind worth trusting.